AngloGold Ashanti Q1 31 March 2026 Earnings Release and Dividend Declaration May 8, 2026 AngloGold Ashanti delivers record free cash flow* of $1.2bn and EBITDA*(4) of $2.3bn • Gold production(1)(2) +1% • Net cash*(4) of $868m • Q1 2026 interim dividend of $585m, or 116 cps • Proposed $2.0bn share repurchase programme announced
Telekom Srbija Secures U.S. EXIM Financing to Accelerate 5G Rollout May 8, 2026 Approval from the Export-Import Bank of the United States will support Serbia’s next-generation telecoms expansion and strengthen U.S.–Serbia technology and economic ties
Esentia Announces Successful Pricing of 6.125% Senior Notes Due 2033 and 6.500% Senior Notes Due 2038 May 8, 2026 Esentia Energy Development, S.A.B. de C.V. (“ESENTIA” or the “Company”), today announced the pricing of U.S.$1,000,000,000.00 aggregate principal amount of its 6.125% Senior Notes due 2033 (the “2033 Notes”) and U.S$1,000,000,000.00 aggregate principal amount of its 6.500% Senior Notes due 2038 (the “2038 Notes” and, together with the 2033 Notes, the “Notes”) to be issued [...]
Prothena Reports First Quarter 2026 Financial Results and Business Highlights May 7, 2026 Net cash provided by operating and investing activities was $28.9 million for the first quarter of 2026; quarter-end cash and restricted cash position was $330.3 million Prothena updates projected full year 2026 net cash used in operating and investing actives to be $18 to $23 million (versus prior guidance $50 to $55 million) and expects to end the year with approximately $273 million (midpoint) in cash, cash equivalents and restricted cash Novo Nordisk obtained Fast Track designation from the U.S. FDA for coramitug (PRX004) for the treatment of ATTR amyloidosis with cardiomyopathy and paid Prothena a $50 million clinical milestone payment related to Phase 3 enrollment Roche presented several clinical updates supporting the potential of prasinezumab for the treatment of Parkinson’s disease at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD™ 2026) Prothena has completed the Phase 1 study for PRX019. Prothena could potentially earn a $55 million clinical milestone payment if Bristol Myers Squibb decides to advance the program; BMS decision expected by year-end 2026 Prothena initiated a share repurchase program to be conducted in 2026 for up to $100 million if deemed appropriate
Avantra 26 Reduces SAP Incident Resolution Times by 60% With New AI-Powered Intelligence May 7, 2026 New release transforms SAP incident response, turning hours of expert analysis into seconds with AI-powered insight
83% of Restaurants Are Invisible in AI Search: New Uberall Report Reveals the Discovery Gap Reshaping the Quick Service Restaurant Industry May 7, 2026 Industry-first benchmark study analyzes how ChatGPT, Gemini, Perplexity, Copilot and Google AI Overviews recommend restaurants
NEAM Limited Hires Giri Singh May 7, 2026 New England Asset Management Limited (NEAM Limited) announces that Giri Singh has joined NEAM Limited’s London Branch as Head of Business Development, Europe. He will be responsible for expanding the firm’s UK and European insurance asset management business. Graham Kirk, Managing Director, NEAM Limited commented, “We’re very excited to bring someone of Giri’s experience and [...]
Algoma Central Corporation Reports Financial Results for the 2026 First Quarter May 7, 2026 Focused fleet growth, strategic opportunities, and built-in adaptability across domestic and international operations drove a resilient first quarter
Wunderkind and Bloomreach Launch Native Integration to Convert Anonymous Traffic into Revenue May 7, 2026 New integration brings Wunderkind’s identity and decisioning into Bloomreach, helping brands recognize more customers, enrich journeys, and drive incremental revenue — without changing workflows.
Silence Therapeutics Highlights Recent Business Achievements and Reports First Quarter 2026 Financial Results May 7, 2026 Phase 2 SANRECO trial of divesiran, a first-in-class siRNA for polycythemia vera (PV), on-track for topline results in August 2026